Loading
Cardiac Imaging and Diagnostics / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Journal of Cardiovascular Development and Disease · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a case report of acute ST-elevation myocardial infarction in a 58-year-old woman with HER2-positive breast cancer occurring after multimodal anti-tumor therapy (chemotherapy, dual HER2-targeted therapy, and left breast radiotherapy). The patient had pre-existing coronary artery calcification and angiographically confirmed multivessel atherosclerotic disease with subtotal left circumflex occlusion; the case suggests a possible temporal association between cancer therapy and acute coronary event but does not establish causation or quantify risk.
Case report. Single 58-year-old female with HER2-positive breast cancer; pre-treatment imaging showed coronary artery calcification.. Intervention: Chemotherapy, dual HER2-targeted therapy, and left breast radiotherapy.
58-year-old female with HER2-positive breast cancer developed acute STEMI following chemotherapy, dual HER2-targeted therapy, and left breast radiotherapy Pre-treatment chest CT identified coronary artery calcification Angiography revealed subtotal occlusion of left circumflex middle segment extending to first obtuse marginal branch with multivessel atherosclerotic lesions
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing patients receiving multimodal cancer therapy should maintain awareness that anti-tumor treatments may accelerate coronary atherosclerosis, particularly in those with baseline subclinical coronary disease, and have a low threshold for evaluating acute cardiac symptoms. This case does not provide epidemiological data to guide risk stratification or prevention strategies.
A single case report with no control group, describing a temporal association between cancer therapy and acute MI; raises a mechanistic hypothesis but provides no quantified risk or causal evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing patients receiving multimodal cancer therapy should maintain awareness that anti-tumor treatments may accelerate coronary atherosclerosis, particularly in those with baseline subclinical coronary disease, and have a low threshold for evaluating acute cardiac symptoms. This case does not provide epidemiological data to guide risk stratification or prevention strategies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cardiovascular toxicity associated with anti-tumor therapies is garnering increased attention. Anti-tumor therapies may elevate the risk of acute coronary syndrome, particularly in patients with underlying subclinical atherosclerosis. In this context, a 58-year-old female patient with HER2-positive breast cancer experienced an acute ST-segment elevation myocardial infarction following chemotherapy, dual HER2-targeted therapy, and radiotherapy to the left breast. Prior to the initiation of anti-tumor treatment, chest-computed tomography had identified coronary artery calcification. Angiographic evaluation revealed subtotal occlusion of the middle segment of the left circumflex artery extending to the first obtuse marginal branch, accompanied by multivessel coronary atherosclerotic lesions. Coronary blood flow was restored following emergency interventional treatment. This case indicates that multimodal anti-tumor therapy may facilitate the progression of coronary atherosclerosis, thereby elevating the risk of acute coronary events.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.